{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:02:41Z","timestamp":1790683361389,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK","award":["Study 217091"],"award-info":[{"award-number":["Study 217091"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40744-026-00878-7","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T07:31:58Z","timestamp":1786174318000},"page":"1325-1340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous Belimumab Demonstrates Consistent Steady-State Pharmacokinetics and is Well Tolerated in Paediatric Patients with SLE in China: An Open-Label Study"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05917288","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Caifeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiguo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihua","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haomin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"issue":"1","key":"878_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/acr.20648","volume":"64","author":"MB Urowitz","year":"2012","unstructured":"Urowitz MB, Gladman DD, Iba\u00f1ez D, Fortin PR, Bae SC, Gordon C, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res. 2012;64(1):132\u20137.","journal-title":"Arthritis Care Res"},{"key":"878_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejim.2023.02.004","volume":"112","author":"M Zen","year":"2023","unstructured":"Zen M, Salmaso L, Barbiellini Amidei C, Fedeli U, Bellio S, Iaccarino L, et al. Mortality and causes of death in systemic lupus erythematosus over the last decade: data from a large population-based study. Eur J Intern Med. 2023;112:45\u201351.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"878_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-00985-0","volume":"23","author":"A Charras","year":"2021","unstructured":"Charras A, Smith E, Hedrich CM. Systemic lupus erythematosus in children and young people. Curr Rheumatol Rep. 2021;23(3):20.","journal-title":"Curr Rheumatol Rep"},{"key":"878_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940416","volume":"13","author":"F Chen","year":"2022","unstructured":"Chen F, Zheng Y, Chen X, Wen Z, Xu Y, Yang J, et al. Belimumab in childhood systemic lupus erythematosus: a review of available data. Front Immunol. 2022;13:940416.","journal-title":"Front Immunol"},{"issue":"8","key":"878_CR5","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/art.34472","volume":"64","author":"LT Hiraki","year":"2000","unstructured":"Hiraki LT, Feldman CH, Liu J, Alarcon GS, Fischer MA, Winkelmayer WC, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum. 2000;64(8):2669\u201376.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"878_CR6","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S2352-4642(24)00172-X","volume":"8","author":"S Gao","year":"2016","unstructured":"Gao S, Yu Z, Ma X, Sun J, Ren A, Gao S, et al. Childhood-onset systemic lupus erythematosus in China, 2016-21: a nationwide study. Lancet Child Adolesc Health. 2016;8(10):762\u201372.","journal-title":"Lancet Child Adolesc Health"},{"issue":"14","key":"878_CR7","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1177\/0961203316644333","volume":"25","author":"N Ambrose","year":"2016","unstructured":"Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford MW, Isenberg DA. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016;25(14):1542\u201350.","journal-title":"Lupus"},{"issue":"2","key":"878_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.pcl.2012.03.007","volume":"59","author":"DM Levy","year":"2012","unstructured":"Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin N Am. 2012;59(2):345\u201364.","journal-title":"Pediatr Clin N Am"},{"issue":"11","key":"878_CR9","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1177\/09612033211028653","volume":"30","author":"RA Levy","year":"2021","unstructured":"Levy RA, Gonzalez-Rivera T, Khamashta M, Fox NL, Jones-Leone A, Rubin B, et al. 10 years of belimumab experience: what have we learnt? Lupus. 2021;30(11):1705\u201321.","journal-title":"Lupus"},{"issue":"4","key":"878_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/ar4256","volume":"15","author":"R Mina","year":"2013","unstructured":"Mina R, Brunner HI. Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Res Ther. 2013;15(4):218.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"878_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40272-021-00457-z","volume":"23","author":"VC Trindade","year":"2021","unstructured":"Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An update on the management of childhood-onset systemic lupus erythematosus. Paediatr Drugs. 2021;23(4):331\u201347.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"878_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15\u201329.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"878_CR13","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1002\/art.11299","volume":"48","author":"KP Baker","year":"2003","unstructured":"Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253\u201365.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"878_CR14","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/art.23678","volume":"58","author":"M Petri","year":"2008","unstructured":"Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(8):2453\u20139.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"878_CR15","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918\u201330.","journal-title":"Arthritis Rheum"},{"issue":"9767","key":"878_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721\u201331.","journal-title":"Lancet"},{"issue":"5","key":"878_CR17","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","volume":"69","author":"W Stohl","year":"2017","unstructured":"Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69(5):1016\u201327.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"878_CR18","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/art.40861","volume":"71","author":"DJ Wallace","year":"2019","unstructured":"Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(7):1125\u201334.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"878_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","volume":"77","author":"F Zhang","year":"2018","unstructured":"Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77(3):355\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"878_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","volume":"78","author":"HA Blair","year":"2018","unstructured":"Blair HA, Duggan ST. Belimumab: a review in systemic lupus erythematosus. Drugs. 2018;78(3):355\u201366.","journal-title":"Drugs"},{"key":"878_CR21","unstructured":"FDA approves Benlysta (belimumab) Autoinjector for children with systemic lupus erythematosus [press release]. 2024."},{"issue":"13","key":"878_CR22","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1177\/0961203316642309","volume":"25","author":"SW Yapa","year":"2016","unstructured":"Yapa SW, Roth D, Gordon D, Struemper H. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus phase 3 program. Lupus. 2016;25(13):1448\u201355.","journal-title":"Lupus"},{"key":"878_CR23","unstructured":"China\u2019s National Medical Products Administration approves Benlysta (belimumab) for adult patients with active lupus nephritis [press release]. 2022."},{"key":"878_CR24","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.ard.2025.06.1928","volume":"84","author":"C Li","year":"2025","unstructured":"Li C, Zhang J, Yu H, Li Z, Yang S, Lu M, et al. A Phase 4, multicentre, open-label study of intravenous belimumab in paediatric patients with active systemic lupus erythematosus in China. Ann Rheum Dis. 2025;84:2261\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"878_CR25","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.clinthera.2017.07.039","volume":"39","author":"K Pascoe","year":"2017","unstructured":"Pascoe K, Lobosco S, Bell D, Hoskin B, Chang DJ, Pobiner B, et al. Patient- and physician-reported satisfaction with systemic lupus erythematosus treatment in US clinical practice. Clin Ther. 2017;39(9):1811\u201326.","journal-title":"Clin Ther"},{"issue":"1","key":"878_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40271-017-0276-2","volume":"11","author":"E Dashiell-Aje","year":"2018","unstructured":"Dashiell-Aje E, Harding G, Pascoe K, DeVries J, Berry P, Ramachandran S. Patient evaluation of satisfaction and outcomes with an autoinjector for self-administration of subcutaneous belimumab in patients with systemic lupus erythematosus. Patient. 2018;11(1):119\u201329.","journal-title":"Patient"},{"issue":"6","key":"878_CR27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/acr.25700","volume":"78","author":"HI Brunner","year":"2026","unstructured":"Brunner HI, Ant\u00f3n J, Calvo-Penad\u00e9s I, Dimelow R, Horneff G, Kamphuis S, et al. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous belimumab in pediatric patients with systemic lupus erythematosus: a multicenter, open-label trial. Arthritis Care Res. 2026;78(6):761\u201370.","journal-title":"Arthritis Care Res"},{"issue":"10","key":"878_CR28","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","volume":"79","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"878_CR29","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/art.40511","volume":"70","author":"A Doria","year":"2018","unstructured":"Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, et al. Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with systemic lupus erythematosus. Arthritis Rheumatol. 2018;70(8):1256\u201364.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"878_CR30","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/cpdd.889","volume":"10","author":"R Dimelow","year":"2021","unstructured":"Dimelow R, Ji B, Struemper H. Pharmacokinetics of belimumab in children with systemic lupus erythematosus. Clin Pharmacol Drug Dev. 2021;10(6):622\u201333.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"878_CR31","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s40744-021-00366-0","volume":"8","author":"X Meng","year":"2021","unstructured":"Meng X, Wang Q, Wu S, Pu D, Zhang A, Fang S, et al. Pharmacokinetics and safety of intravenous and subcutaneous auto-injector single-dose belimumab in healthy Chinese volunteers: a phase 1, randomized, open-label study. Rheumatol Ther. 2021;8(4):1711\u201324.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"878_CR32","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/bcp.16263","volume":"91","author":"J Wu","year":"2025","unstructured":"Wu J, Zhou X, Dimelow R, Marshall S. Inter-regional pharmacokinetics and exposure-response analyses of belimumab in patients with system lupus erythematosus. Br J Clin Pharmacol. 2025;91(2):374\u201385.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00878-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00878-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00878-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:29:20Z","timestamp":1790681360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00878-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["878"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00878-7","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Caifeng Li, Junmei Zhang, Meiping Lu, Haiguo Yu, Li Sun, Qihua Feng, and Zhihui Li have nothing to disclose. Jane Chen and Haomin Qiu are employed by GSK and hold financial equities in GSK. Tiantian Liu is employed by GSK. Junyi Wu was employed by GSK at the time of the study and holds financial equities in GSK. Xuan Zhou was employed by GSK at the time of the study. This study is independent of the current affiliations for Junyi Wu and Xuan Zhou, with no further conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by all relevant institutional review boards (IRBs) or ethics committees and was conducted in accordance with the Declaration of Helsinki 2008 and its later amendments, Council for International Organisation of Medical Sciences (CIOM) International Ethical Guidelines, applicable International Organisation for Standardisation 14155 medical device guidelines, the European Medical Device Regulation 2017\/745 for clinical device research and other applicable laws and regulations. The master ethics committee was the Medical Ethics Committee of Beijing Children\u2019s Hospital, and all participating IRBs or ethics committees are listed in Table S2. Patients and their legal representatives were informed that study participation was voluntary. Prior to study enrolment, investigative sites obtained signed informed consent from patients or their legally authorized representative that met the requirements of 21 Code of Federal Regulations 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability Act requirements, where applicable, and the IRB\/Independent Ethic Committee (IEC) or study centre.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}